AZD4573 in Novel Combinations With Anti-cancer Agents in Patients With Advanced Blood Cancer
Completed · Phase 1/Phase 2
Conditions studied: Advanced Haematological Malignancies
In brief
This is a modular, multicentre, open-label, non-randomised, Phase I/II, dose-setting and expansion study including an intra-participants dose ramp up. AZD4573 will be administered intravenously, in novel combinations with anti-cancer agents, to participants with relapsed/refractory (r/r) haematological malignancies.
Key facts
- Study ID
- NCT04630756
- Run by
- AstraZeneca
- People needed
- 40
- Starts
- 2021-02-17
- Expected to finish
- 2025-02-27
- Last updated by the study team
- 2025-04-09
Who can join
Age: 18 and older, up to 130. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Research Site — Duarte, California, United States
- Research Site — La Jolla, California, United States
- Research Site — Houston, Texas, United States
- Research Site — Salt Lake City, Utah, United States
- Research Site — Clayton, Australia
- Research Site — Nedlands, Australia
- Research Site — Québec, Quebec, Canada
- Research Site — Lille, France
- Research Site — Dublin, Ireland
- Research Site — Galway, Ireland
- Research Site — Krakow, Poland
- Research Site — Seoul, South Korea
- Research Site — Seoul, South Korea
- Research Site — Seoul, South Korea
- Research Site — Barcelona, Spain
- Research Site — Palma de Mallorca, Spain
- Research Site — Plymouth, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.